92.4M → 92.4M shares held
A big owner of Eli Lilly sold $862K of Eli Lilly shares. Nobody planned it ahead of time.
Traded Nov 5, 2025 · Filed Nov 6, 2025
A big owner of Eli Lilly sold $28.7M of Eli Lilly shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$28,716,846
Shares × reported transaction price
6 days after results of Oct 30, 2025, 91 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $925.81 on Nov 5, 2025, within 1% of its 52-week high, after a 25% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $929.72 (Mar 3, 2025), 99% of the way up, from 250 adjusted closes. 30 trading days earlier: $741.85 on Sep 24, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Retevmo on Nov 20, 2025, 15 days after this trade.
New use approved (efficacy supplement). Active ingredient: Selpercatinib. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +10.9% | +0.1% | +10.8% |
| 30 days | +7.9% | +1.9% | +6.0% |
| 90 days | +10.4% | +1.0% | +9.4% |
| 180 days | +6.8% | +9.4% | -2.6% |
Past results only. Not a forecast.
92.4M → 92.4M shares held
A big owner of Eli Lilly sold $862K of Eli Lilly shares. Nobody planned it ahead of time.
92.4M → 92.4M shares held
A big owner of Eli Lilly sold $1.36M of Eli Lilly shares. Nobody planned it ahead of time.
92.2M → 92.2M shares held
A big owner of Eli Lilly sold $5.59M of Eli Lilly shares. Nobody planned it ahead of time.